Explore all of our publications and interviews in academic journals and mainstream media using the filter and search functions.
CMS's Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs
The administration has proposed a loophole in the Medicaid Best Price rules that would dismiss linking the drug's effectiveness to its price.
HA Blog 07/06/2020
Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students
Medical students' education covers topics spanning health, disease, and treatment, but what about drug pricing and their role as prescribers?
Medical Science Educator 01/13/2021
Who Is Sowing Seeds of Confusion About The QALY?
Industry sponsorship of patient advocacy groups opposing the QALY threatens to undermine not just the QALY but also an objective analysis of policy decisions.
Health Affairs 07/24/2020
Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead
Value-based pricing has emerged as an alternative to prices determined by what the market will bear. But which agreements are truly "value-based"?
Value in Health 03/29/2021
US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
No Results Found